Prognosis of macular edema secondary to central retinal vein occlusion (CRVO) has been shown to improve with anti-vascular endothelial growth factor (anti-VEGF) treatment in clinical trials and real-world clinical settings1. The gene discussed is VEGFA; the disease is macular retinal edema.